BREANNE SABBATINO: Open Payments
NPI 1245011527 · STOCKTON, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$839 in 37 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $839
Food & beverage: $839
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $139 |
| Lilly USA, LLC | 4 | $81 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $79 |
| Lundbeck LLC | 3 | $73 |
| GlaxoSmithKline, LLC. | 3 | $68 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $57 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Viatris Specialty LLC | 2 | $39 |
| Exact Sciences Corporation | 2 | $37 |
Products named: Ozempic, REXULTI, JARDIANCE, GEMTESA, CAPLYTA, NEXLETOL, TRELEGY ELLIPTA, MOUNJARO.
Industry payments across CA — which companies pay providers there.
